The Clinical Efficacy of Imiglucerase versus Eliglustat in Patients with Gaucher's Disease Type 1: A Systematic Review

Azita Nabizadeh, Bahman Amani, Maliheh Kadivar, Mahdi Toroski, Akbar Abdollahi Asl, Yahya Bayazidi, Mahdi Mojahedian, Majid Davari, Azita Nabizadeh, Bahman Amani, Maliheh Kadivar, Mahdi Toroski, Akbar Abdollahi Asl, Yahya Bayazidi, Mahdi Mojahedian, Majid Davari

Abstract

Gaucher's disease (GD) is one of the most common lysosomal diseases in humans. It results from β-glucosidase deficiency and leads to necrosis, especially in macrophages with the accumulation of glucosylceramidase in cells. Most of the deleterious effects of the disease are seen in the liver, spleen, and bone marrow. The aim of this study was to compare the efficacy of Imiglucerase with Eliglustat in treating patients with GD. PubMed/Medline, Cochrane Library, Scopus, Web of Science, Embase, and Google Scholar were searched from inception to August, 2018. Predefined inclusion criteria for included studies were based on search methodology and are as follows: All randomized, quasi-randomized controlled, and cohort studies about patients with GD Type 1 that Imiglucerase was compared with Eliglustat were included. Two authors independently choose the papers based on the inclusion criteria. From 2979 recognized studies, three studies including two randomized clinical trials and one cohort study were recognized to meet the inclusion criteria. The primary outcomes were hemoglobin level, platelets count, liver, and spleen size, and the secondary outcomes were the immunological side effects of the medicines and bone complications. The results showed that there is no meaningful difference between the two medicines in terms of increasing blood hemoglobin, platelets count, and reducing the liver and spleen size. The findings of this review showed that both medicines are effective in the treatment of GD Type 1 and there is no statistically significant difference between their efficacies.

Keywords: Eliglustat; Gaucher disease; Imiglucerase.

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Process of the screening of studies
Figure 2
Figure 2
Electronic search strategy in PubMed database

References

    1. Bohra V, Nair V. Gaucher's disease. Indian J Endocrinol Metab. 2011;15:182–6.
    1. Grabowski GA, Andria G, Baldellou A, Campbell PE, Charrow J, Cohen IJ, et al. Pediatric non-neuronopathic Gaucher disease: Presentation, diagnosis and assessment. Consensus statements. Eur J Pediatr. 2004;163:58–66.
    1. Sheth J, Mistri M, Sheth F, Shah R, Bavdekar A, Godbole K, et al. Burden of lysosomal storage disorders in India: Experience of 387 affected children from a single diagnostic facility. JIMD Rep. 2014;12:51–63.
    1. Zimran A. How I treat Gaucher disease. Blood. 2011;118:1463–71.
    1. Mistry PK, Weinthal JA, Weinreb NJ. Disease state awareness in Gaucher disease: A Q and A expert roundtable discussion. Clin Adv Hematol Oncol. 2012;10:1–16.
    1. Barranger JA, Brady RO, Grabowski GA, Mankin H, Mistry PK, Weinreb NJ, et al. Position statement: National Gaucher Foundation Medical Advisory Board, January 7, 2014. Am J Hematol. 2014;89:457–8.
    1. Koprivica V, Stone DL, Park JK, Callahan M, Frisch A, Cohen IJ, et al. Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. Am J Hum Genet. 2000;66:1777–86.
    1. Amaral O, Lacerda L, Santos R, Pinto RA, Aerts H, Sa Miranda MC, et al. Type 1 Gaucher disease: Molecular, biochemical, and clinical characterization of patients from northern portugal. Biochem Med Metab Biol. 1993;49:97–107.
    1. Mistry PK, Cappellini MD, Lukina E, Ozsan H, Mach Pascual S, Rosenbaum H, et al. A reappraisal of Gaucher disease-diagnosis and disease management algorithms. Am J Hematol. 2011;86:110–5.
    1. Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, et al. Replacement therapy for inherited enzyme deficiency – Macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med. 1991;324:1464–70.
    1. Gonzalez DE, Turkia HB, Lukina EA, Kisinovsky I, Dridi MF, Elstein D, et al. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, phase 3 study. Am J Hematol. 2013;88:166–71.
    1. Grabowski GA, Barton NW, Pastores G, Dambrosia JM, Banerjee TK, McKee MA, et al. Enzyme therapy in type 1 Gaucher disease: Comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med. 1995;122:33–9.
    1. Elstein D, Hadas-Halpern I, Itzchaki M, Lahad A, Abrahamov A, Zimran A, et al. Effect of low-dose enzyme replacement therapy on bones in Gaucher disease patients with severe skeletal involvement. Blood Cells Mol Dis. 1996;22:104–11.
    1. Pastores GM, Weinreb NJ, Aerts H, Andria G, Cox TM, Giralt M, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol. 2004;41:4–14.
    1. Weinreb NJ, Aggio MC, Andersson HC, Andria G, Charrow J, Clarke JT, et al. Gaucher disease type 1: Revised recommendations on evaluations and monitoring for adult patients. Semin Hematol. 2004;41:15–22.
    1. Chen M, Wang J. Gaucher disease: Review of the literature. Arch Pathol Lab Med. 2008;132:851–3.
    1. Shayman JA. Eliglustat tartrate: Glucosylceramide synthase inhibitor treatment of type 1 Gaucher disease. Drugs Future. 2010;35:613–20.
    1. Caudle KE, Klein TE, Hoffman JM, Muller DJ, Whirl-Carrillo M, Gong L, et al. Incorporation of pharmacogenomics into routine clinical practice: The clinical pharmacogenetics implementation consortium (CPIC) guideline development process. Curr Drug Metab. 2014;15:209–17.
    1. Cox TM. Eliglustat tartrate, an orally active glucocerebroside synthase inhibitor for the potential treatment of Gaucher disease and other lysosomal storage diseases. Curr Opin Investig Drugs. 2010;11:1169–81.
    1. Cox TM, Aerts JM, Andria G, Beck M, Belmatoug N, Bembi B, et al. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: A position statement. J Inherit Metab Dis. 2003;26:513–26.
    1. Radin NS. Treatment of Gaucher disease with an enzyme inhibitor. Glycoconj J. 1996;13:153–7.
    1. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.
    1. Pai M, McCulloch M, Gorman JD, Pai N, Enanoria W, Kennedy G, et al. Systematic reviews and meta-analyses: An illustrated, step-by-step guide. Natl Med J India. 2004;17:86–95.
    1. Higgins JP, Altman DG, Sterne JA, editors. Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration. 2011. [Last updated on 2011 Mar 25; Last accessed on 2017 May 25]. Available from: .
    1. Cox TM, Drelichman G, Cravo R, Balwani M, Burrow TA, Martins AM, et al. Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: A phase 3, randomised, open-label, non-inferiority trial. Lancet. 2015;385:2355–62.
    1. Pleat R, Cox TM, Burrow TA, Giraldo P, Goker-Alpan O, Rosenbloom BE, et al. Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial. Mol Genet Metab Rep. 2016;9:25–8.
    1. Ibrahim J, Underhill LH, Taylor JS, Angell J, Peterschmitt MJ. Clinical response to eliglustat in treatment-naïve patients with Gaucher disease type 1: Post-hoc comparison to imiglucerase-treated patients enrolled in the International Collaborative Gaucher Group Gaucher Registry. Mol Genet Metab Rep. 2016;8:17–9.
    1. Belmatoug N, Di Rocco M, Fraga C, Giraldo P, Hughes D, Lukina E, et al. Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe. Eur J Intern Med. 2017;37:25–32.
    1. Smid BE, Hollak CE. A systematic review on effectiveness and safety of eliglustat for type 1 gaucher disease. Expert Opin Orphanet Drugs. 2014;2:523–9.
    1. Weinreb NJ, Barranger JA, Charrow J, Grabowski GA, Mankin HJ, Mistry P, et al. Guidance on the use of miglustat for treating patients with type 1 Gaucher disease. Am J Hematol. 2005;80:223–9.
    1. Elstein D, Zimran A. Review of the safety and efficacy of imiglucerase treatment of Gaucher disease. Biologics. 2009;3:407–17.
    1. Shayman JA. The design and clinical development of inhibitors of glycosphingolipid synthesis: Will invention be the mother of necessity? Trans Am Clin Climatol Assoc. 2013;124:46–60.
    1. Cox TM, Drelichman G, Cravo R, Balwani M, Burrow TA, Martins AM, et al. Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy. Blood. 2017;129:2375–83.
    1. Mistry PK, Lukina E, Ben Turkia H, Amato D, Baris H, Dasouki M, et al. Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: The ENGAGE randomized clinical trial. JAMA. 2015;313:695–706.
    1. Jung O, Patnaik S, Marugan J, Sidransky E, Westbroek W. Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for parkinson disease. Expert Rev Proteomics. 2016;13:471–9.
    1. Aflaki E, Westbroek W, Sidransky E. The complicated relationship between Gaucher disease and parkinsonism: Insights from a Rare disease. Neuron. 2017;93:737–46.
    1. Ortega RA, Torres PA, Swan M, Nichols W, Boschung S, Raymond D, et al. Glucocerebrosidase enzyme activity in GBA mutation Parkinson's disease. J Clin Neurosci. 2016;28:185–6.
    1. Migdalska-Richards A, Schapira AH. The relationship between glucocerebrosidase mutations and Parkinson disease. J Neurochem. 2016;139(Suppl 1):77–90.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit